FN Archimer Export Format
PT J
TI Artefactual source of 2-hydroxypyridine
BT 
AF Wilmes, Paul
   Trezzi, Jean-Pierre
   Aho, Velma
   Jäger, Christian
   Schade, Sebastian
   Janzen, Annette
   Hickl, Oskar
   Kunath, Benoit
   Thomas, Mélanie
   Schmit, Kristopher
   Garcia, Pierre
   Sciortino, Alessia
   Martin-Gallausiaux, Camille
   Halder, Rashi
   Huarte, Oihane Uriarte
   Heurtaux, Tony
   Heins-Marroquin, Ursula
   Gomez-Giro, Gemma
   Weidenbach, Katrin
   Delacour, Léa
   Laczny, Cédric
   Novikova, Polina
   Ramiro-Garcia, Javier
   Singh, Randolph
   Andújar, Begoña Talavera
   Lebrun, Laura
   Daujeumont, Annegrait
   Habier, Janine
   Dong, Xiangyi
   Gavotto, Floriane
   Heintz-Buschart, Anna
   Schneider, Jochen
   Jehmlich, Nico
   von Bergen, Martin
   Schymanski, Emma
   Schmitz, Ruth
   Schwamborn, Jens
   Glaab, Enrico
   Linster, Carole
   Kitami, Toshimori
   Buttini, Manuel
   May, Patrick
   Trenkwalder, Claudia
   Oertel, Wolfgang
   Mollenhauer, Brit
AS 1:1,7;2:1,2;3:1;4:1;5:3,4;6:5;7:1;8:1;9:1,6;10:1,6;11:1,6;12:1,6;13:1;14:1;15:1,6;16:6,7;17:1;18:1;19:8;20:1;21:1;22:1;23:1;24:1,9;25:1;26:1;27:1;28:1;29:1;30:1;31:10;32:1,11;33:12;34:12;35:1;36:8;37:1;38:1;39:1;40:13;41:1,6;42:1;43:4,14;44:5;45:4,5;
FF 1:;2:;3:;4:;5:;6:;7:;8:;9:;10:;11:;12:;13:;14:;15:;16:;17:;18:;19:;20:;21:;22:;23:;24:;25:;26:;27:;28:;29:;30:;31:;32:;33:;34:;35:;36:;37:;38:;39:;40:;41:;42:;43:;44:;45:;
C1 Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
   Integrated Biobank of Luxembourg, Luxembourg Institute of Health, Dudelange, Luxembourg
   Department of Neurology, University Medical Center Göttingen, Göttingen, Germany
   Paracelsus-Elena-Klinik, Kassel, Germany
   Department of Neurology, Philipps-University Marburg, Marburg, Germany
   Luxembourg Center of Neuropathology (LCNP), Dudelange, Luxembourg
   Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, Belvaux, Luxembourg
   Institute for General Microbiology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany
   Unité Contamination Chimique des Ecosystèmes Marins, IFREMER (Institut Français de Recherche pour l’Exploitation de la Mer), Nantes, France
   Biosystems Data Analysis, Swammerdam Institute for Life Sciences, Faculty of Science, University of Amsterdam, Amsterdam, The Netherlands
   Departments of Internal Medicine and Psychiatry and Psychotherapy, Saarland University Medical Center at Homburg/Saar, Homburg, Germany
   Helmholtz-Zentrum für Umweltforschung – UFZ GmbH, Department Molekulare Systembiologie, Leipzig, Germany
   RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan
   Department of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany
C2 UNIV LUXEMBOURG, LUXEMBOURG
   LUXEMBOURG INST HEALTH, LUXEMBOURG
   UNIV GOTTINGEN, GERMANY
   PARACELSUS-ELENA-KLINIK, GERMANY
   UNIV MARBURG, GERMANY
   LCNP, LUXEMBOURG
   UNIV LUXEMBOURG, LUXEMBOURG
   UNIV KIEL, GERMANY
   Unité Contamination Chimique des Ecosystèmes Marins, IFREMER (Institut Français de Recherche pour l’Exploitation de la Mer), Nantes, France
   UNIV AMSTERDAM, NETHERLANDS
   UNIV SAARLAND, GERMANY
   HELMHOLTZ ZENTRUM, GERMANY
   RIKEN IMS, JAPAN
   UNIV GOTTINGEN, GERMANY
TC 0
UR https://archimer.ifremer.fr/doc/00785/89741/95233.pdf
   https://archimer.ifremer.fr/doc/00785/89741/95234.pdf
   https://archimer.ifremer.fr/doc/00785/89741/95235.pdf
   https://archimer.ifremer.fr/doc/00785/89741/95236.xlsx
   https://archimer.ifremer.fr/doc/00785/89741/109629.pdf
LA English
DT Article
AB Patients with Parkinson’s disease (PD) exhibit differences in their gut microbiomes compared to healthy individuals. Although differences have most commonly been described in the abundances of bacterial taxa, changes to viral and archaeal populations have also been observed. Mechanistic links between gut microbes and PD pathogenesis remain elusive but could involve molecules that promote α-synuclein aggregation. Here, we show that 2-hydroxypyridine (2-HP) represents a key molecule for the pathogenesis of PD. We observe significantly elevated 2-HP levels in faecal samples from patients with PD or its prodrome, idiopathic REM sleep behaviour disorder (iRBD), compared to healthy controls. 2-HP is correlated with the archaeal species Methanobrevibacter smithii and with genes involved in methane metabolism, and it is detectable in isolate cultures of M. smithii. We demonstrate that 2-HP is selectively toxic to transgenic α-synuclein overexpressing yeast and increases α-synuclein aggregation in a yeast model as well as in human induced pluripotent stem cell derived enteric neurons. It also exacerbates PD-related motor symptoms, α-synuclein aggregation, and striatal degeneration when injected intrastriatally in transgenic mice overexpressing human α-synuclein. Our results highlight the effect of an archaeal molecule in relation to the gut-brain axis, which is critical for the diagnosis, prognosis, and treatment of PD. 
PY 2022
PD JUN
SO Preprint
PU Research Square Platform LLC
DI 10.21203/rs.3.rs-1827631/v2
ID 89741
ER

EF